Zevra Therapeutics Stock Sees 117% Upside Potential After Patent Extension for MIPLYFFA
ZVRA Stock ‘Way Undervalued’? Analyst Sees 117% Upside After Patent Extends Exclusivity Till 2041 For Sole Approved Drug
Image: Asianet Newsable
Zevra Therapeutics' stock surged 14% following the extension of its patent for MIPLYFFA, its only FDA-approved drug, ensuring market exclusivity until November 2041. Analysts predict a 117% upside, bolstered by the drug's strong revenue growth and positive market sentiment.
- 01The new patent for MIPLYFFA extends exclusivity until November 2041, preventing generic competition.
- 02MIPLYFFA generated $87.4 million in net revenue in 2025, a significant increase from $10.1 million in 2024.
- 03Zevra's total net revenue for 2025 reached $106.5 million, with MIPLYFFA accounting for over 82%.
- 04Cantor Fitzgerald analyst Kristen Kluska raised the price target for ZVRA to $34, maintaining an 'Overweight' rating.
- 05All nine analysts covering ZVRA rate it 'Buy' or higher, with an average price target suggesting a potential upside of 117%.
Advertisement
In-Article Ad
Zevra Therapeutics (ZVRA) experienced a 14% increase in stock price after announcing an extension of patent protection for MIPLYFFA, its only FDA-approved therapy for Niemann-Pick disease type C. The new patent, which blocks generic versions until November 2041, enhances investor confidence and secures future cash flows. MIPLYFFA's revenue surged to $87.4 million in 2025, representing a dramatic rise from $10.1 million in 2024, and comprising over 82% of Zevra's total net revenue of $106.5 million. This strong performance transitioned the company from a net loss in 2024 to a profit of $83.2 million in 2025. Following the patent news, Cantor Fitzgerald analyst Kristen Kluska raised the price target for ZVRA from $24 to $34, citing a significant positive impact on cash flow analysis. Retail sentiment on Stocktwits shifted from bearish to bullish, with analysts unanimously rating ZVRA as a 'Buy', indicating a potential 117% upside from its last closing price.
Advertisement
In-Article Ad
The patent extension is expected to secure long-term revenue streams for Zevra, benefiting investors and potentially leading to increased employment and investment in the company.
Advertisement
In-Article Ad
Reader Poll
What do you think about the future of ZVRA stock?
Connecting to poll...
Read the original article
Visit the source for the complete story.